Skip to main content

Irene Hernández Hernández

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca
Irene Hernández Hernández

Irene Hernández Hernández

Irene Hernández Hernández

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Insulin resistance in type 2 diabetes: unraveling the pathogenic mechanism between organs

IP: José Raul Herance Camacho
Collaborators: Fiorella Dellepiane Clarke, Joan Castell Conesa, Nuria Roson Gradaille, Carolina Aparicio Gomez, Alberto Roque Pérez, Mònica Velasco Nuño, Insulin resistance in type 2 diabetes: unraveling the pathogenic mechanism between organs, Irene Hernández Hernández, Maria Nazarena Pizzi, Insulin resistance in type 2 diabetes: unraveling the pathogenic mechanism between organs
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI20/01588
Duration: 01/01/2021 - 30/06/2025

Role of sarcopenia in the evolution of morbidly obese patients who undergo bariatric surgery. Study of cohorts and mechanisms involved.

IP: Andreea Ciudin Mihai
Collaborators: Oscar González López, Fiorella Ximena Palmas Candia, Marina Giralt Arnaiz, Marta Comas Martínez, Rosa Burgos Peláez, Irene Hernández Hernández, Enzamaría Fidilio Meli, Efráin Santiago Cordero Vázquez, Cristina Gamez Cenzano
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI20/01086
Duration: 01/01/2021 - 31/12/2024

Control of the adipose-pancreatic crosstalk by mitochondrial metabolism in adipose tissues: implications in the development of diet-induced type 2 diabetes

IP: Josep A Villena Delgado
Collaborators: Rosario Pardo Diaz, Berta Pares Bofill, Irene Hernández Hernández
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 145200
Reference: RTI2018-099250-B-I00
Duration: 01/01/2019 - 30/09/2022

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Sergio Hinojosa Sanz

Sergio Hinojosa Sanz

Cardiovascular Diseases
Read more
Gemma Parramon Puig

Gemma Parramon Puig

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Susana  Garcia  Bayona

Susana Garcia Bayona

Molecular Imaging and Therapy
Read more
Basilio Rodriguez  Diez

Basilio Rodriguez Diez

Senior researcher
Systemic Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.